MAGIC-01 (A study of a new vaccine against Marburg virus in adults aged 18 – 55 years)
Research type
Research Study
Full title
A phase 1, first-in-human safety and immunogenicity study of a Marburg virus vaccine, ChAdOx1 Marburg, in healthy volunteers aged 18 – 55 years in the UK
IRAS ID
1009218
Contact name
Angela Minassian
Contact email
Sponsor organisation
University of Oxford Research Governance, Ethics & Assurance (RGEA) Team
ISRCTN Number
ISRCTN97679658
Research summary
Marburg virus is a member of the same family as Ebolavirus and causes a life-threatening disease (Marburg virus disease, MVD) which can be fatal in up to 88% of people. It is naturally carried by Egyptian fruit bats, but humans can be infected and pass it on to others. Outbreaks have recently occurred in several countries in sub-Saharan Africa, including in Equatorial Guinea in 2023. There is currently no licensed vaccine or treatment for MVD.
A potential vaccine against Marburg virus, ChAdOx1 Marburg, has been developed at the University of Oxford. Using the same technology as the Oxford-AstraZeneca ChAdOx1 nCoV-2019 vaccine, use of the ChAdOx1 Marburg vaccine could generate antibodies that would prevent MVD from taking hold.
In this study the ChAdOx1 Marburg vaccine will be given for the first time to 46 healthy adults aged 18-55. They will receive two doses of the vaccine 3 months apart. The main aim of the study is to find out whether the vaccine is safe and what side effects it may cause. A second aim is to look at how the human immune system responds to the vaccine.REC name
London - Brent Research Ethics Committee
REC reference
24/LO/0243
Date of REC Opinion
29 Apr 2024
REC opinion
Further Information Favourable Opinion